Shares of Proteon Therapeutics Inc (NASDAQ:PRTO) have been assigned a consensus rating of “Hold” from the six brokerages that are covering the stock, MarketBeat.com reports. Five investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $3.43.
A number of research analysts recently weighed in on PRTO shares. Zacks Investment Research lowered Proteon Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 18th. HC Wainwright reaffirmed a “hold” rating and set a $2.30 price objective on shares of Proteon Therapeutics in a report on Wednesday, November 8th. Finally, Robert W. Baird reaffirmed a “hold” rating and set a $2.00 price objective on shares of Proteon Therapeutics in a report on Friday, November 10th.
In other Proteon Therapeutics news, Director James E. Flynn acquired 110,557 shares of the company’s stock in a transaction that occurred on Thursday, November 30th. The shares were purchased at an average price of $1.75 per share, with a total value of $193,474.75. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have purchased 122,852 shares of company stock worth $216,533 in the last ninety days. 36.30% of the stock is currently owned by corporate insiders.
Proteon Therapeutics (NASDAQ:PRTO) traded up $0.05 during trading on Monday, hitting $1.90. The stock had a trading volume of 43,100 shares, compared to its average volume of 26,275. Proteon Therapeutics has a twelve month low of $1.10 and a twelve month high of $2.75. The stock has a market capitalization of $33.48, a PE ratio of -0.86 and a beta of 1.62.
WARNING: “Proteon Therapeutics Inc (PRTO) Given Consensus Rating of “Hold” by Brokerages” was first reported by Community Financial News and is the property of of Community Financial News. If you are accessing this piece on another site, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The original version of this piece can be read at https://www.com-unik.info/2018/01/08/proteon-therapeutics-inc-prto-given-consensus-rating-of-hold-by-brokerages.html.
About Proteon Therapeutics
Proteon Therapeutics, Inc is a late-stage biopharmaceutical company, which focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. The Company is involved in research and development activities. The Company’s product candidate, product candidate, vonapanitase, formerly PRT-201, is a recombinant human elastase that it is developing to manage vascular access failure in patients with chronic kidney disease undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access.
What are top analysts saying about Proteon Therapeutics? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Proteon Therapeutics and related companies.